UK – NICE backing for AZ’ Tagrisso

AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

In clinical trials, the drug was shown to provide an overall survival benefit of more than three years when used as a first-line treatment compared to first-generation medicines in the same class.

Clinical data also show that Tagrisso has a more significant impact on cancer that has spread to the central nervous system and a favourable side effect profile, AZ noted.

Lung cancer is currently the most common cause of cancer death in the UK, accounting for one in five (21%) of all cancer deaths.